Epilepsy drug found to thwart nervous system tumor growth
What if an already-Food and Drug Administration-approved drug could help treat a particularly troublesome disorder? Researchers at Washington University School of Medicine in St. Louis have found just such a use for one drug, according to a press release by the institution published earlier this month.
An old drug with a new purpose
The condition is neurofibromatosis type 1 (Nf1) and the drug is lamotrigine, an epilepsy drug. People suffering from Nf1 develop tumors on nerves throughout their bodies that are usually benign but can still cause serious medical issues such as blindness.
The new research reveals that neurons carrying a mutation in the Nf1 gene are hyperexcitable and that suppressing this hyperactivity with lamotrigine stops tumor growth in mice.
“Tumors are very common in people with Nf1,” said senior author David H. Gutmann, MD, Ph.D., the Donald O. Schnuck Family Professor and director of the Washington University Neurofibromatosis Center.
“We’ve shown that we can block the growth of Nf1 tumors by shutting off neuronal hyperexcitability. We’ve done it now a couple of different ways, and there’s no question that repurposing antiepileptics is an effective way to inhibit tumor growth, at least in mice. This underscores the critical role that neurons play in tumor biology.”
To test this new application of an older drug, the researchers studied neurons from mice with and without Nf1 gene mutations. They found that neurons from mice with tumor-causing Nf1 mutations fired electrical impulses more frequently than neurons from normal mice, releasing molecules that increased the growth of brain and nerve tumors.
Through further research, they were able to attribute this hyperexcitability to a dysfunctional ion channel that changed the baseline electrical activity inside the neurons. They then proceeded to also examine mice with an Nf1 mutation seen in people with NF1 who do not develop brain or nerve tumors.
Hyperexcitable Nf1-mutant neurons
The neurons from mice with this specific Nf1 mutation were not hyperexcitable and did not develop tumors. Since hyperexcitable neurons are also a feature of epilepsy, the drug lamotrigine, therefore, targets the same ion channel disrupted in hyperexcitable Nf1-mutant neurons.
To test if the drug could also work for Nf1, the researchers gave lamotrigine to a group of Nf1-mutant mice that develop optic nerve tumors. They then compared the results with a group of mice receiving placebos and found that the mice that had received the drug had smaller tumors, which were no longer growing.
“The mutation in the Nf1 gene changes the basic biology of the neuron,” Gutmann said. “During development, neurons form first and tell the rest of the brain how to form. If you have a mutation that affects how neurons behave, that may change everything about how the brain gets set up during development. Nothing we’ve tried so far to prevent learning disabilities has worked. Maybe this discovery could lead to new treatments for the learning and cognitive problems in children with NF1.
“I’m very excited about the scientific and medical implications of these findings. Not hyperexcited,” he added, “but excited.”
The study was published in Nature magazine.
Neuronal activity is emerging as a driver of central and peripheral nervous system cancers. Here, we examined neuronal physiology in mouse models of the tumor predisposition syndrome Neurofibromatosis-1 (NF1), with different propensities to develop nervous system cancers. We show that central and peripheral nervous system neurons from mice with tumor-causing Nf1 gene mutations exhibit hyperexcitability and increased secretion of activity-dependent tumor-promoting paracrine factors. We discovered a neurofibroma mitogen (COL1A2) produced by peripheral neurons in an activity-regulated manner, which increases NF1-deficient Schwann cell proliferation, establishing that neurofibromas are regulated by neuronal activity. In contrast, mice with the Arg1809Cys Nf1 mutation, found in NF1 patients lacking neurofibromas or optic gliomas, do not exhibit neuronal hyperexcitability or develop these NF1-associated tumors. The hyperexcitability of tumor-prone Nf1-mutant neurons results from reduced NF1-regulated hyperpolarization-activated cyclic nucleotide-gated (HCN) channel function, such that neuronal excitability, activity-regulated paracrine factor production, and tumor progression are attenuated by HCN channel activation. Collectively, these findings reveal that NF1 mutations act at the level of neurons to modify tumor predisposition by increasing neuronal excitability and activity-regulated paracrine factor production.
Globally-recognized innovative change expert Nigel Barlow on how there has never been a more important time to foster innovation.